The researchers concluded that vaccines made from genetically modified viruses may help the body build an effective immune response to kill tumor cells, whereas monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread, so giving a CCL21 genetically modified DC vaccine with pembrolizumab to treat patients with stage IV nonsmall cell lung cancer may work better. This evidence concerns the gene CCL21 and lung cancer.